Background {#Sec1}
==========

Lymphatic filariasis (LF), a neglected tropical disease estimated by the World Health Organization to affect 940 million people in 54 countries, is targeted for elimination by 2020 \[[@CR1]--[@CR3]\]. LF is not a fatal disease, but it can cause significant morbidity. It is the second leading parasitic cause of disability worldwide, estimated to cause 5.549 million disability-adjusted life years (DALYs) \[[@CR4]\].

Three species of filarial worms, *Wuchereria bancrofti*, *Brugia malayi* and *Brugia timori* are known to cause lymphatic filariasis in humans \[[@CR5]\]. *Wuchereria bancrofti* is responsible for 90% of LF, while *B. malayi* is responsible for most of the remaining infections \[[@CR6]\]. *Brugia malayi* is prevalent in Southeast Asia and southwestern India (Kerala) \[[@CR5]\]. Both *W. bancrofti* and *B. malayi* infections were prevalent in Sri Lanka in the past \[[@CR7]\]. Successful vector control activities targeted at *Mansonia* spp. mosquitoes resulted in complete clearance of brugian filariasis by 1967 \[[@CR7]\].

In 2016, Sri Lanka was acknowledged by World Health Organization (WHO) to have eliminated lymphatic filariasis as a public health problem, following five successful rounds of mass drug administration (MDA) conducted in the endemic areas of the country, from 2002 to 2006 \[[@CR8]\]. During the national LF elimination programme, only bancroftian filariasis was documented in the endemic areas; brugian filariasis was regarded as eliminated decades previously. However, surveillance activities conducted during the post-elimination phase have found cases of brugian filariasis throughout the endemic region \[[@CR9]--[@CR11]\].

Very little is known of the newly emerged brugian filariasis in Sri Lanka. Therefore, this study aimed to investigate age-specific vulnerability to infection and to characterize the re-emergent species of *Brugia* by its periodicity pattern.

Methods {#Sec2}
=======

Study area {#Sec3}
----------

The study was conducted in the district of Gampaha, owing to the high number of cases reported in the past decade (AFC personal communication). Gampaha District, with 2.3 million inhabitants, is the second most populous district in Sri Lanka and comprises of urban, semi-urban and rural populations in a land area of 1387 km^2^ \[[@CR12]\].

Study sites were selected based on the occurrence of cases of brugian filariasis in the recent past. All the cases reported from the District of Gampaha were listed, and the GPS coordinates of their households were recorded during site visits, using a handheld GPS monitor (Montana®610 Garmin handheld GPS Receiver), and mapped using ArcGIS 10. A 500 m buffer zone was demarcated around each case. High-risk areas (hot spots) for transmission of brugian filariasis, defined by the occurrence of two or more positive cases within the 500 m buffer zone were selected as study sites. The 500 m radius area of the study locations was decided to encompass the mean flight range of the vector mosquitoes of the genus *Mansonia* (350 m) \[[@CR13]\] and an adequate number of households. Two areas that fulfilled the above criteria, Pubudugama and Wedamulla, in Medical Officer of Health areas of Wattala and Kelaniya, respectively, were identified as study sites in this manner. A map indicating the locations of the study sites are given in Fig.[1](#Fig1){ref-type="fig"}.Fig. 1Location of recent past positive cases of Brugian filariasis in Gampaha District in Sri Lanka and 500 m buffer zone of each case. The buffer zones (colored in yellow) were taken as study areas

Study population {#Sec4}
----------------

Criteria for enrolment in the study were residence in a study site for over 1 year and age above 1 year. Households were enrolled by random, systematic sampling method and visited by the surveillance team between 16:00 and 19:30 h for collection of basic demographic data. An age-stratified population of 500 individuals from each study location (total of 1000 individuals) was selected for screening. The age stratification was based on criteria relevant to disease exposure and MDA. The age groups were as follows: 1--5 and 6--10 years of age (born after the conclusion of MDA), 11--20 years (mostly school children, who would have been treated under the MDA programme), 21--50 years (adults who received MDA), 51 years and above (MDA recipients with possible past exposure to *B. malayi* infection). Approximately 100 participants were included from each age group.

Surveillance and periodicity study {#Sec5}
----------------------------------

Blood samples were obtained by the house to house screening carried out between 20.00 and 23.00 h during the period December 2016 to June 2017. Two-night blood smears (NBSs) were prepared from each participant (60 μl tri-linear and coin shaped). These were stained with Giemsa and examined microscopically for microfilariae (MF) in two different laboratories: The Department of Parasitology, Faculty of Medicine, University of Kelaniya and the Regional Filariasis Control Unit, Gampaha. Species identification of the MF was based on morphology, namely densely packed nuclei, the presence of two isolated nuclei at the tip of the tail and cephalic space longer than *W. bancrofti* \[[@CR5]\].

Each sample of blood was also examined for IgG4 antibodies to *B. malayi* using the Brugia rapid test kit (BRT) from Brugia Rapid, Reszon Diagnostics International, Malaysia. The BRT was performed as per the manufacturer's instructions in the field, and all positive test results excluding two from non-compliant participants were confirmed by repeat testing. Additional MF positive cases detected at routine surveillance activities of the AFC during this period were also tested for antibody positivity.

The periodicity of a *Brugia* spp. infection detected as described above was studied by quantitative estimation of MF in peripheral blood collected at intervals over 24 h, using the Nucleopore-membrane filtration method \[[@CR14]\]. The *Brugia* spp. MF positive case was a male, 14 years of age, who consented to be repeatedly bled. He was admitted to the local hospital, and one milliliter of heparinized venous blood was obtained at 01:00, 03:00, 05:00, 07:00, 09:00, 13:00, 17:00, 21:00 and 23:00 h under aseptic conditions for MF counts.

Data were entered into an Excel file, and age-group specific infection rates (MF and antibody rates) were calculated for each study location. Microfilaria rate is defined as the blood smears positive for microfilaria expressed as a percentage of the smears examined, and the antibody rate is defined as the number of samples found to be antibody-positive by the BRT, as a percentage of the samples examined. The MF rate and antibody rate is equal to the prevalence if a representative sample of the population is screened by the relevant tests; thus, in this study MF rate and antibody rate indicate MF prevalence and antibody prevalence in the study areas. A periodicity curve was prepared by plotting the MF counts against time.

Results {#Sec6}
=======

A total of 994 persons from Pubudugama (*n* = 467, 47.9%) and Wedamulla (*n* = 527, 53%) with a male: female ratio of 1:1.02 from 325 households (153 in Pubudugama and 172 in Wedamulla) were enrolled and screened for LF infection by NBS. The age group specific LF infection rates are as shown in Table [1](#Tab1){ref-type="table"}. Two MF positive cases were detected at Pubudugama (MF rate, 0.43%) and none were found at Wedamulla (MF rate 0), giving an overall MF rate of 0.2. Of the two MF positives, one person (age group 21--50 years) had a *W. bancrofti* infection while the other (age group 11--20 years) had a *Brugia* spp. infection (Table [1](#Tab1){ref-type="table"}).Table 1Microfilaria and anti-*Brugia* IgG4 antibody positivity according to age groups in Pubudugama and Wedamulla, Sri LankaAge group (years)Number (%) screenedNumber (%) positive for LFPubudugamaWedamullaNBS number (%)BRT Number (%)PubudugamaWedamullaPubudugamaWedamulla1--590 (19.3)88 (16.7)00006--1096 (20.6)101 (19.2)001 (1.04)1 (0.99)11--2091 (19.5)118 (22.4)1(Bm) (1.1)01 (1.09)3 (2.56)21--5097 (20.8)109 (20.7)1(Wb) (1.03)001 (0.92)\>  5193 (19.9)111 (21.1)0002 (1.8)Total467 (47.9)527 (53.0)2 (0.43)02 (0.43)7 (1.34)*Abbreviations*: *Bm B. malayi*, *Wb W. bancrofti*, *NBS* night blood smear, *BRT Brugia* rapid test

The BRT was done on 991 participants with valid test readings obtained in 984 (461 in Pubudugama, and 523 in Wedamulla). Nine participants \[two in Pubudugama, (antibody rate 0.43%) and seven in Wedamulla (antibody rate 1.34%)\] were positive for anti-Brugia IgG4 antibodies (overall antibody rate 0.91) (Table [1](#Tab1){ref-type="table"}). Both MF positive individuals were negative for antibodies by the BRT. The BRT was done on three other MF (*Brugia* spp.) positive cases (all \< 5 years) detected by the AFC during routine surveillance activities and only one of them tested positive for antibodies.

In MF positive individual studied for periodicity (Fig. [2](#Fig2){ref-type="fig"}), MF was observed in the peripheral circulation throughout the day (subperiodic) with peak counts observed at 21.00 h indicating a nocturnally-subperiodic parasite species.Fig. 2Throughout the day MF were positive in the peripheral blood indicating nocturnal sub-periodicity

Discussion {#Sec7}
==========

The overall MF and anti-Brugia antibody rates observed in our study population were 0.20 and 0.91, respectively, which is below the thresholds used to define LF endemicity by WHO (prevalence of MF and filarial-specific antibodies 1% and 2%, respectively) \[[@CR15]\]. A previous survey for anti-*Brugia* antibodies among a paediatric population (mean age 8.5 years) in Pubudugama reported a slightly higher antibody rate of 1.6 \[[@CR9]\]. Although the present survey was restricted to Gampaha District, cases of brugian filariasis are increasingly detected at routine night blood surveys of the endemic region (four and ten MF positive cases in 2015 and 2016, respectively) \[[@CR11], [@CR16]\].

Persistent transmission of LF, after cessation of mass chemotherapy based intervention programs, has been described in Pondicherry (20 years after cessation of a DEC-fortified salt program with mop-up MDA), in Ghana after 14 years of MDA and in American Samoa 8 years after cessation of MDA \[[@CR17]--[@CR19]\]. Although, low MF rates of 0.6--0.7 were described by Ramiah et al. \[[@CR17]\] as safe, with very little likelihood of recrudescence, vigilance is critical at this point to ensure that programmatic gains are sustained.

Two strains of *B. malayi* have been recognized based on the periodicity patterns of MF \[[@CR20], [@CR21]\]. Humans are the only known definitive hosts of the nocturnally periodic form of *B. malayi*, but the nocturnally subperiodic form shows little host specificity with zoonotic reservoirs in primates and feline species (palm civet cats, wild cats and domestic cats) and cause infections in humans as well \[[@CR22]--[@CR24]\]. The *B. malayi* that was prevalent in Sri Lanka in the past was the nocturnally periodic form \[[@CR25]\]. Subperiodic *B. malayi* has been reported in Southeast Asia (Indonesia, Peninsular Malaysia, the Philippines and Thailand) where it has been described as an important zoonosis with animal-to-man and even man-to-man transmission \[[@CR22], [@CR26]\]*.*

*Brugia pahangi,* a parasite of cats and dogs, is another zoonotic filarial parasite that exhibits nocturnal periodicity. Reports of natural *B. pahangi* infections in humans are rare, perhaps because of difficulty in distinguishing between the microfilariae of *B. pahangi* and *B. malayi*, unless special staining techniques are employed \[[@CR22]\]. Recently, several cases of symptomatic *B. pahangi* infections were reported from Malaysia where the identity of the infecting species was established by PCR \[[@CR27]\].

The control of subperiodic *B. malayi* infection poses a great problem as mass treatment of the human population with antifilarials, so effective for periodic *B. malayi*, and *W. bancrofti* does not suffice because the large animal reservoir remains untouched \[[@CR22], [@CR26]\]. Thus the re-emergence of Brugian filariasis infections in Sri Lanka after several decades, is a cause for concern, especially because the nocturnal subperiodicity of the MF suggests a zoonotic infection. Moreover, a recent survey in the Western Province of Sri Lanka has demonstrated a canine reservoir of *B. malayi* infection \[[@CR28]\].

Association of *Brugia* spp. infections with age was not evident in the present survey due the low number of cases detected (one MF and 9 antibody positives, *n* = 10). However, the majority of cases (70%) in the present study occurred among the under 20-year age group.

The rapid diagnostic used in this survey, BRT detects filaria-specific IgG4 antibodies to recombinant antigen BmR1 of *Brugia malayi.* Anti-filarial IgG4 levels have considered being a good indicator of active infection since levels are elevated in active filariasis \[[@CR29]--[@CR31]\] and decline post-treatment \[[@CR32], [@CR33]\]. Thus, detection of anti-filarial IgG4 antibodies has been used for epidemiological assessment of filariasis \[[@CR34]\].

In the present survey, BRT was positive in only one of four microfilaraemia cases that were positive by NBS, whereas nine BRT positive individuals were MF negative. A multicenter laboratory evaluation of BRT for detection of brugian filariasis have reported sensitivities of \> 95% with 100% specificity \[[@CR35]\]. However, a field validation of BRT done in Malaysia reported a lower sensitivity (87%) as compared to microscopy of NBS, but BRT detected about ten times more cases than microscopy \[[@CR36]\]. The latter findings are comparable with the results of the present study. The lower sensitivity of BRT in the field than in laboratory evaluations was attributed to the small number of microfilaremic individuals and difficulties encountered in performing the test in remote villages of Malaysia \[36\]. The small number of microfilaraemia patients in the present study may be the explanation for the lower sensitivity of the BRT for detecting them. Perhaps, genetic predisposition to infection and capacity to mount antibody responses are dissociated, and this only becomes noticeable when prevalence is low.

The periodicity data obtained in this study cannot be generalized to all the re-emergent *Brugia* infections in Sri Lanka, as only a single case was studied due to the paucity of eligible cases. This limitation should be addressed by further periodicity studies and establishment of species identity by molecular methods.

Conclusions {#Sec8}
===========

There was the low-level persistence of bancroftian filariasis and re-emergence of brugian filariasis in Gampaha District, Sri Lanka. One case of re-emergent *Brugia* species infection was found to exhibit nocturnal sub-periodicity, suggesting a probable zoonotic origin. This report highlights the implications of an untouched zoonotic reservoir of *B. malayi* infection coupled with minimal on-going vector control activities in Sri Lanka, which could threaten the successes achieved in LF control.
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